© Reuters. FILE PHOTO: A syringe is stuffed with a dose of Pfizer’s COVID-19 vaccine at a pop-up group vaccination middle on the Gateway World Christian Center in Valley Stream, New York, U.S., February 23, 2021. REUTERS/Brendan McDermid
(Reuters) -Pfizer Inc stated on Monday its COVID-19 vaccine supplied robust long-term safety in opposition to the virus in a late-stage research performed amongst adolescents aged 12 to fifteen years.
A two-dose sequence of the vaccine was 100% efficient in opposition to COVID-19, measured seven days by means of over 4 months after the second dose, the corporate stated.
The long-term data will help deliberate submissions for full-regulatory approval of the vaccine in the age group in the United States and worldwide.
Pfizer (NYSE:) and BioNTech will search clearance for a 30 micrograms dose of the vaccine for these aged 12 and above.
The vaccine was licensed for emergency use in individuals aged 12-15 years by the U.S. Food & Drug Administration in May, and granted full approval to be used in individuals aged 16 and above in August.
Fusion Media or anybody concerned with Fusion Media won’t settle for any legal responsibility for loss or injury on account of reliance on the knowledge together with data, quotes, charts and purchase/promote alerts contained inside this web site. Please be absolutely knowledgeable relating to the dangers and prices related to buying and selling the monetary markets, it is among the riskiest funding kinds potential.